Plasma ADAMTS-13 levels and the risk of myocardial infarction: An individual patient data meta-analysis

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 8, 2015, Pages 1396-1404

  Maino, A ^a,b   Siegerink, B ^a,c   Lotta, L A ^b   Crawley, J T B ^d   le Cessie, S ^a   Leebeek, F W G ^e   Lane, D A ^d   Lowe, G D O ^f   Peyvandi, F ^b   Rosendaal, F R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MILAN   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

ADAMTS13 protein, human; Blood coagulation; Meta analysis; Myocardial infarction; Risk factors; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMATIC REVIEW; ADOLESCENT; BLOOD; CHI SQUARE DISTRIBUTION; DOWN REGULATION; ENZYMOLOGY; MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL; YOUNG ADULT;

ADAM PROTEINS; ADOLESCENT; ADULT; BIOMARKERS; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OBSERVATIONAL STUDIES AS TOPIC; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84937825245     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13032     Document Type: Article

References (35)

1. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-63.
2. Sadler JE. von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-18.
3. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
4. Willeit P, Thompson A, Aspelund T, Rumley A, Eiriksdottir G, Lowe G, Gudnason V, Di Angelantonio E. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS ONE 2013; 8: e55175.
5. van Schie MC, de Maat MP, Isaacs A, van Duijn CM, Deckers JW, Dippel DW, Leebeek FW. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011; 117: 1393-9.
6. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Myocardial Infarction Genetics Consortium, Wellcome Trust Case Control Consortium, Martinelli N, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011; 377: 383-92.
7. Lotta LA, Peyvandi F. Addressing the complexity of cardiovascular disease by design. Lancet 2011; 377: 356-8.
8. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-9.
9. Jin SY, Tohyama J, Bauer RC, Cao NN, Rader DJ, Zheng XL. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler Thromb Vasc Biol 2012; 32: 1817-23.
10. Xiao J, Jin SY, Xue J, Sorvillo N, Voorberg J, Zheng XL. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis. Arterioscler Thromb Vasc Biol 2011; 31: 2261-9.
11. Fujioka M, Hayakawa K, Mishima K, Kunizawa A, Irie K, Higuchi S, Nakano T, Muroi C, Fukushima H, Sugimoto M, Banno F, Kokame K, Miyata T, Fujiwara M, Okuchi K, Nishio K. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010; 115: 1650-3.
12. Andersson HM, Siegerink B, Luken BM, Crawley JT, Algra A, Lane DA, Rosendaal FR. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012; 119: 1555-60.
13. Peyvandi F, Hollestelle MJ, Palla R, Merlini PA, Feys HB, Vanhoorelbeke K, Lenting PJ, Mannucci PM. Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. J Thromb Haemost 2010; 8: 1653-6.
14. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007; 109: 1998-2000.
15. Sonneveld MA, de Maat MP, Leebeek FW. von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 2014; 28: 167-78.
16. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010; 340: c221. doi: 10.1136/bmj.c221.
17. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
18. Mathew T, Nordstrom K. Comparison of one-step and two-step meta-analysis models using individual patient data. Biom J 2010; 52: 271-87.
19. Harrell FE. Regression Modelling Strategies. New York: Springer-Verlag, 2001. ISBN: 0-387-95232-2.
20. Horii M, Uemura S, Uemura M, Matsumoto M, Ishizashi H, Imagawa K, Iwama H, Takeda Y, Kawata H, Nakajima T, Fujimura Y, Saito Y. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels 2008; 23: 301-7.
21. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 2006; 4: 2490-3.
22. Matsukawa M, Kaikita K, Soejima K, Fuchigami S, Nakamura Y, Honda T, Tsujita K, Nagayoshi Y, Kojima S, Shimomura H, Sugiyama S, Fujimoto K, Yoshimura M, Nakagaki T, Ogawa H. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007; 100: 758-63.
23. Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008; 6: 583-8.
24. Bongers TN, de Bruijne EL, Dippel DW, de Jong AJ, Deckers JW, Poldermans D, de Maat MP, Leebeek FW. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009; 207: 250-4.
25. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-292.
26. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gomez Garcia EB, Dippel DW, Leebeek FW. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37: 2672-7.
27. Lambers M, Goldenberg NA, Kenet G, Kirkham FJ, Manner D, Bernard T, Mesters RM, Junker R, Stoll M, Nowak-Gottl U. Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study. Ann Neurol 2013; 73: 58-64.
28. Gandhi C, Ahmad A, Wilson KM, Chauhan AK. ADAMTS-13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. J Thromb Haemost 2014; 12: 255-60.
29. Gandhi C, Motto DG, Jensen M, Lentz SR, Chauhan AK. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. Blood 2012; 120: 5224-30.
30. Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A, Vucelic D, Pizzuti M, Mannucci PM, Peyvandi F. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 2010; 151: 488-94.
31. Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H, Tomiyama Y, Miyata T. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107: 3161-6.
32. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007; 120(Suppl. 1): S5-9.
33. Gombos T, Mako V, Cervenak L, Papassotiriou J, Kunde J, Harsfalvi J, Forhecz Z, Pozsonyi Z, Borgulya G, Janoskuti L, Prohaszka Z. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009; 102: 573-80.
34. Bennett CL, Kim B, Zakarija A, Bandarenko N, Pandey DK, Buffie CG, McKoy JM, Tevar AD, Cursio JF, Yarnold PR, Kwaan HC, De Masi D, Sarode R, Raife TJ, Kiss JE, Raisch DW, Davidson C, Sadler JE, Ortel TL, Zheng XL, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007; 50: 1138-43.
35. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-40.